JP2022523201A5 - - Google Patents
Info
- Publication number
- JP2022523201A5 JP2022523201A5 JP2021549575A JP2021549575A JP2022523201A5 JP 2022523201 A5 JP2022523201 A5 JP 2022523201A5 JP 2021549575 A JP2021549575 A JP 2021549575A JP 2021549575 A JP2021549575 A JP 2021549575A JP 2022523201 A5 JP2022523201 A5 JP 2022523201A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- hydrogen
- compound
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19159299 | 2019-02-26 | ||
| EP19159299.7 | 2019-02-26 | ||
| PCT/EP2020/054897 WO2020173935A1 (en) | 2019-02-26 | 2020-02-25 | New isoindolinone substituted indoles and derivatives as ras inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523201A JP2022523201A (ja) | 2022-04-21 |
| JP2022523201A5 true JP2022523201A5 (https=) | 2023-03-03 |
| JP7426398B2 JP7426398B2 (ja) | 2024-02-01 |
Family
ID=65598476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549575A Active JP7426398B2 (ja) | 2019-02-26 | 2020-02-25 | Ｒａｓ阻害剤としての新規イソインドリノン置換インドールおよび誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12281099B2 (https=) |
| EP (1) | EP3931188B1 (https=) |
| JP (1) | JP7426398B2 (https=) |
| CN (1) | CN113474340B (https=) |
| WO (1) | WO2020173935A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| EP4143196A4 (en) | 2020-04-29 | 2024-04-17 | Relay Therapeutics, Inc. | PI3K-A INHIBITORS AND METHODS OF USE THEREOF |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| GB202104609D0 (en) | 2021-03-31 | 2021-05-12 | Sevenless Therapeutics Ltd | New Treatments for Pain |
| EP4313151A1 (en) | 2021-03-31 | 2024-02-07 | Sevenless Therapeutics Limited | Sos1 inhibitors and ras inhibitors for use in the treatment of pain |
| CN115232108B (zh) | 2021-04-23 | 2025-04-18 | 领泰生物医药(绍兴)有限公司 | Sos1降解剂及其制备方法和应用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| EP4416131A4 (en) * | 2021-10-15 | 2025-07-30 | Genetolead Inc | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF |
| TW202334136A (zh) * | 2021-11-03 | 2023-09-01 | 美商傳達治療有限公司 | PI3Kα抑制劑及其製造與使用方法 |
| WO2023114973A1 (en) | 2021-12-17 | 2023-06-22 | Shure Acquisition Holdings, Inc. | Adaptive acoustic echo cancellation for a stereo audio signal |
| CN119212994A (zh) | 2021-12-17 | 2024-12-27 | 建新公司 | 作为shp2抑制剂的吡唑并吡嗪化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4473970A4 (en) | 2022-03-31 | 2026-01-21 | Eisai R&D Man Co Ltd | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4598538A1 (en) | 2022-10-05 | 2025-08-13 | Sevenless Therapeutics Limited | New treatments for pain |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| AU2023439518A1 (en) | 2023-04-06 | 2025-08-28 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200901212A1 (ru) * | 2007-03-29 | 2010-04-30 | Новартис Аг | 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний |
| CA2904393A1 (en) | 2013-03-15 | 2014-09-25 | Araxes Pharma Llc | Covalent inhibitors of kras g12c |
| EP3055290B1 (en) | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
| WO2017015562A1 (en) | 2015-07-22 | 2017-01-26 | Araxes Pharma Llc | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
| HUE068392T2 (hu) | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3523289A1 (en) * | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| US11136308B2 (en) * | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| WO2021148581A1 (en) * | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
-
2020
- 2020-02-25 WO PCT/EP2020/054897 patent/WO2020173935A1/en not_active Ceased
- 2020-02-25 JP JP2021549575A patent/JP7426398B2/ja active Active
- 2020-02-25 EP EP20707599.5A patent/EP3931188B1/en active Active
- 2020-02-25 US US17/430,011 patent/US12281099B2/en active Active
- 2020-02-25 CN CN202080016480.4A patent/CN113474340B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022523201A5 (https=) | ||
| US10844080B2 (en) | Compositions and methods for inhibiting arginase activity | |
| RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
| US9221801B2 (en) | Inhibitors of histone demethylases | |
| JP2021532162A5 (https=) | ||
| JP2023528623A5 (https=) | ||
| JP2004511466A5 (https=) | ||
| RS61996B1 (sr) | Kompozicije i postupci za inhibiranje aktivnosti arginaze | |
| JP2010500415A5 (https=) | ||
| JP2022549222A5 (https=) | ||
| JP2014527082A5 (https=) | ||
| JP2015510886A5 (https=) | ||
| JP2008535903A5 (https=) | ||
| PE20061305A1 (es) | Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas | |
| RU2014145856A (ru) | Азотсодержащее гетероциклическое соединение или его соль | |
| RU2013151174A (ru) | Замещенные пиримидинилпирролы, активные в качестве ингибиторов киназы | |
| RU2008119842A (ru) | Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1 | |
| JP2002516817A5 (https=) | ||
| JP2016510000A5 (ja) | 治療用化合物 | |
| JP2014520108A5 (https=) | ||
| JP2007505044A5 (https=) | ||
| JP2023532128A5 (https=) | ||
| JP2021500334A5 (https=) | ||
| CA2427660A1 (en) | Biphenylcarboxamides useful as lipid lowering agents | |
| JP2023538524A5 (https=) |